AOLS (Aeolus Pharmaceuticals) Shares Buyback Ratio %: 0.00 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aeolus Pharmaceuticals Shares Buyback Ratio %?

Aeolus Pharmaceuticals AOLS -99.00% Shares Buyback Ratio % is 0.00 as of Sep. 22, 2026.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Aeolus Pharmaceuticals's current shares buyback ratio was 0.00%.

Aeolus Pharmaceuticals Shares Buyback Ratio % Related Terms

Aeolus Pharmaceuticals Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Shares Buyback Ratio % Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.74 -114.48 -0.97 -0.06 -11.89

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.35 0.00 0.00 0.00 0.00

Aeolus Pharmaceuticals Shares Buyback Ratio % Calculation

Aeolus Pharmaceuticals's Shares Buyback Ratio for the fiscal year that ended in Sep. 2016 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Sep. 2015 ) - Shares Outstanding (EOP) (A: Sep. 2016 )) / Shares Outstanding (EOP) (A: Sep. 2015 )
=(135.930068 - 152.085825) / 135.930068
=-11.89%

Aeolus Pharmaceuticals's Shares Buyback Ratio for the quarter that ended in Jun. 2017 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2017 ) - Shares Outstanding (EOP) (A: Jun. 2017 )) / Shares Outstanding (EOP) (A: Mar. 2017 )
=(152.085825 - 152.085825) / 152.085825
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of 0.00 mean?
Aeolus Pharmaceuticals (AOLS) has a Shares Buyback Ratio % of 0.00 as of Sep. 22, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' Shares Buyback Ratio % too high?
Aeolus Pharmaceuticals' current Shares Buyback Ratio % is 0.00.
How does Aeolus Pharmaceuticals' Shares Buyback Ratio % compare to RDGL and PCYN?
Aeolus Pharmaceuticals' Shares Buyback Ratio % of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Drug Manufacturers company?
A good Shares Buyback Ratio % depends on the Drug Manufacturers industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Aeolus Pharmaceuticals and its competitors. Aeolus Pharmaceuticals's current Shares Buyback Ratio % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current Shares Buyback Ratio % of 0.00. The current Shares Buyback Ratio % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current Shares Buyback Ratio % is 0.00 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.